You just read:

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting

News provided by

Viracta Therapeutics, Inc.

Jun 03, 2019, 09:00 ET